source
- GSK to acquire Nuvalent for $10.6 billion, expanding its lung-cancer pipelineGSK announced it will buy Cambridge-based biotech Nuvalent for $10.6 billion, paying $124 per share, a 26% premium to the biotech's recent average share price. Nuvalent has two lung‑cancer drugs u…
- GSK to acquire cancer drug developer Nuvalent for $10.6 billionGSK announced an agreement to purchase Nuvalent, a company focused on cancer therapies, in a transaction valued at $10.6 billion. The acquisition is intended to broaden GSK’s oncology portfolio an…